• Recruiting

NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM

Updated: Sep 27

NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

pvx-410 vaccine smoldering myeloma

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering Multiple Myeloma


This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma.

The following intervention will be involved in this study:

Lenalidomide

Citarinostat (CC-96241)

PVX-410


Sponsor

Massachusetts General Hospital


Collaborators

Celgene

OncoPep, Inc.

 

ClinicalTrials.gov Identifier: NCT02886065

Official Title: A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma

First Posted : September 1, 2016

Click here for details on ClinicalTrials.gov

 

Hiltonol : National Cancer Institute

Citarinostat : National Cancer Institute

PVX-410 : National Cancer Institute


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

 

Drug: Hiltonol

Drug: Citarinostat

Drug: Lenalidomide


Biological: PVX-410

 

Locations

United States, Massachusetts

United States, North Carolina

United States, Ohio



Posts Archive